🚀 VC round data is live in beta, check it out!
RemeGen Valuation Multiples
Discover revenue and EBITDA valuation multiples for RemeGen and similar public comparables like Dr Reddy's Laboratories, Cipla, Exelixis, Lupin and more.
RemeGen Overview
About RemeGen
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.
Founded
2008
HQ
Employees
3.5K
Website
Sectors
Financials (LTM)
EV
$11B
RemeGen Financials
RemeGen reported last 12-month revenue of $642M and EBITDA of $244M.
In the same LTM period, RemeGen generated $578M in gross profit, $244M in EBITDA, and $226M in net income.
Revenue (LTM)
RemeGen P&L
In the most recent fiscal year, RemeGen reported revenue of $251M and EBITDA of ($161M).
RemeGen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $642M | XXX | $251M | XXX | XXX | XXX |
| Gross Profit | $578M | XXX | $200M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | $244M | XXX | ($161M) | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | (64%) | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | (80%) | XXX | XXX | XXX |
| Net Profit | $226M | XXX | ($215M) | XXX | XXX | XXX |
| Net Margin | 35% | XXX | (86%) | XXX | XXX | XXX |
| Net Debt | — | — | $265M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
RemeGen Stock Performance
RemeGen has current market cap of $11B, and enterprise value of $11B.
Market Cap Evolution
RemeGen's stock price is $19.52.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11B | $11B | -1.1% | XXX | XXX | XXX | $-0.38 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRemeGen Valuation Multiples
RemeGen trades at 17.1x EV/Revenue multiple, and 44.9x EV/EBITDA.
EV / Revenue (LTM)
RemeGen Financial Valuation Multiples
As of April 19, 2026, RemeGen has market cap of $11B and EV of $11B.
Equity research analysts estimate RemeGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
RemeGen has a P/E ratio of 48.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11B | XXX | $11B | XXX | XXX | XXX |
| EV (current) | $11B | XXX | $11B | XXX | XXX | XXX |
| EV/Revenue | 17.1x | XXX | 43.8x | XXX | XXX | XXX |
| EV/EBITDA | 44.9x | XXX | (68.4x) | XXX | XXX | XXX |
| EV/EBIT | 52.8x | XXX | (54.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 19.0x | XXX | 54.8x | XXX | XXX | XXX |
| P/E | 48.7x | XXX | (51.1x) | XXX | XXX | XXX |
| EV/FCF | 131.3x | XXX | (51.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified RemeGen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
RemeGen Margins & Growth Rates
RemeGen's revenue in the last 12 month grew by 48%.
RemeGen's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
RemeGen's rule of 40 is 182% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
RemeGen's rule of X is 369% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
RemeGen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 48% | XXX | 87% | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | (64%) | XXX | XXX | XXX |
| EBITDA Growth | 95% | XXX | (159%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 182% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 369% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 26% | XXX | 55% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | 19% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 28% | XXX | 90% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 160% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
RemeGen Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| RemeGen | XXX | XXX | XXX | XXX | XXX | XXX |
| Dr Reddy's Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Cipla | XXX | XXX | XXX | XXX | XXX | XXX |
| Exelixis | XXX | XXX | XXX | XXX | XXX | XXX |
| Lupin | XXX | XXX | XXX | XXX | XXX | XXX |
| BioMarin Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
RemeGen M&A Activity
RemeGen acquired XXX companies to date.
Last acquisition by RemeGen was on XXXXXXXX, XXXXX. RemeGen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by RemeGen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRemeGen Investment Activity
RemeGen invested in XXX companies to date.
RemeGen made its latest investment on XXXXXXXX, XXXXX. RemeGen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by RemeGen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout RemeGen
| When was RemeGen founded? | RemeGen was founded in 2008. |
| Where is RemeGen headquartered? | RemeGen is headquartered in China. |
| How many employees does RemeGen have? | As of today, RemeGen has over 3K employees. |
| Is RemeGen publicly listed? | Yes, RemeGen is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of RemeGen? | RemeGen trades under 688331 ticker. |
| When did RemeGen go public? | RemeGen went public in 2020. |
| Who are competitors of RemeGen? | RemeGen main competitors are Dr Reddy's Laboratories, Cipla, Exelixis, Lupin. |
| What is the current market cap of RemeGen? | RemeGen's current market cap is $11B. |
| What is the current revenue of RemeGen? | RemeGen's last 12 months revenue is $642M. |
| What is the current revenue growth of RemeGen? | RemeGen revenue growth (NTM/LTM) is 48%. |
| What is the current EV/Revenue multiple of RemeGen? | Current revenue multiple of RemeGen is 17.1x. |
| Is RemeGen profitable? | Yes, RemeGen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of RemeGen? | RemeGen's last 12 months EBITDA is $244M. |
| What is RemeGen's EBITDA margin? | RemeGen's last 12 months EBITDA margin is 38%. |
| What is the current EV/EBITDA multiple of RemeGen? | Current EBITDA multiple of RemeGen is 44.9x. |
| What is the current FCF of RemeGen? | RemeGen's last 12 months FCF is $84M. |
| What is RemeGen's FCF margin? | RemeGen's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of RemeGen? | Current FCF multiple of RemeGen is 131.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.